{"entity":{"id":"nct05798897","kind":"trial","name":"Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma","aka":[],"tldr":"A phase 1 trial of MT-601 run by Marker Therapeutics, Inc., now recruiting.","summary":"Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma is a phase 1 interventional study registered as NCT05798897 by Marker Therapeutics, Inc., with 79 participants planned, started 2023-01-02. Conditions recorded: Non-Hodgkin Lymphoma, Adult, Non-Hodgkin Lymphoma, Refractory, Non-Hodgkin Lymphoma, Relapsed, Non Hodgkin Lymphoma, Hodgkin Lymphoma, Hodgkin Lymphoma, Adult and Hodgkin's Lymphoma, Relapsed, Adult. Interventions recorded: MT-601.","status":"recruiting","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT05798897","url":"https://clinicaltrials.gov/study/NCT05798897"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["non-hodgkin-lymphoma","hodgkin-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":["mt-601"],"companies":["marker-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05798897","phase":"1","setting":"A Phase 1 Study of Patient-Derived Multi-Tumor-Associated Antigen-Specific T Cells (MT-601) Administered to Patients With Relapsed or Refractory Non-Hodgkin and Hodgkin Lymphoma (APOLLO)","sponsor":"Marker Therapeutics, Inc.","enrolled":79,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05798897/","neighbours":{"cancer":[{"id":"hodgkin-lymphoma","kind":"cancer","name":"Hodgkin lymphoma","route":"/cancers/hodgkin-lymphoma/"},{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}],"drug":[{"id":"mt-601","kind":"drug","name":"MT-601","route":"/drugs/mt-601/"}],"company":[{"id":"marker-therapeutics","kind":"company","name":"Marker Therapeutics","route":"/companies/marker-therapeutics/"}]}}